Research record
Ipilimumab
Ipilimumab is a CTLA-4 checkpoint inhibitor, a different immune checkpoint category from PD-1 drugs.
What this is
Ipilimumab is a CTLA-4 checkpoint inhibitor, a different immune checkpoint category from PD-1 drugs.
Why it may come up
- combination immunotherapy
- selected monotherapy contexts
- depends on treatments already tried
What not to assume
- No toxicity-management details beyond care-team prompts.
At a glance
Ipilimumab
- Type
- Immunotherapy
- Mutation result
- any
- Where
- US, Korea, Japan, China, EU
- Evidence status
- Approved in listed place
- Last checked
- 2026-05-20
What we know
- NCI melanoma drug and treatment pages support ipilimumab as a melanoma drug/category.
What is unclear
- Current country-specific use and reimbursement require local source mapping.
Questions to ask
- Is ipilimumab being discussed alone or with nivolumab?
- What side effects are most important to understand before starting?
- How does this fit after prior PD-1 therapy?
Related cohort stories
Lived experience only
Experiences with nivolumab plus ipilimumab in melanoma
A cohort-style thread for families to describe questions, side effects discussed, and what changed during care.